Kornimate/medical-research-clean huggingface dataset:
effects of a cognitive gait dual task with smartglasses in stroke patients

Conditions: Stroke

Summary: the aim of this study is to find out to determine changes in gait, dual-task interference, cognition, and fall scores during a cognitive walking dual task on a treadmill while wearing augmented reality-based smartglasses in stroke patients. before the experiment, the investigators measure the subjects general characteristics, gait, cognition, dual-task interference, and fall risk. this will be done 3 times a week for 30 minutes for 4 weeks. group 1 will perform a cognitive task with smart glasses and a gait task on a treadmill at the same time. the training will consist of 10 minutes of treadmill walking without incline, followed by 5 minutes of rest, followed by 10 minutes of treadmill walking with incline, followed by 5 minutes of rest. group 2 will perform only treadmill walking without the cognitive task. same as the experimental group: 10 minutes without treadmill incline, followed by 5 minutes rest, followed by 10 minutes treadmill incline, followed by 5 minutes rest. at the end of the 4-week training program, the investigators will measure walking ability, cognitive performance, dual-task interference, and fall risk as assessed before the experiment.


Eligibility criteria:
inclusion criteria: * participants have hemiplegia from a stroke * able to walk 10 meters independently without assistive devices * stable health to participate in the study protocol and interventions exclusion criteria: * have comorbidities or disabilities other than stroke that may interfere with gait training * have an uncontrolled medical condition for which exercise is contraindicated. * have a neurological or orthopedic condition that may interfere with the study

Keywords: stroke cognitive training gait cognition fall
sleep intervention for kids and parents: a self-management pilot study

Conditions: Sleep Disturbance; Asthma

Summary: behavioral intervention for 6-11 year children with persistent asthma and sleep disturbance and a parent with sleep disturbance.


Eligibility criteria:
inclusion criteria (child): * children 6-11 years * child diagnosis of asthma with prescription for daily medication * able to understand english (child) * sleep disturbance per cshq (child \>= 41) and/or \< 9 hours of sleep per night exclusion criteria (child) * parent reported diagnosis of traumatic brain injury, developmental delay, autism spectrum disorder, attention deficit hyperactivity disorder (adhd), obstructive sleep apnea, cancer * positive sleep related breathing disorder screening (obstructive sleep apnea screening) inclusion criteria (parent) * 18 years or older * able to understand and read english * lives with child 50% of time or more * is child's legal guardian * has reliable access to internet * \>/= 5 on pittsburgh sleep quality index or \<7 hours overnight reported sleep exclusion criteria (parent) * diagnosed obstructive sleep apnea or sleep disordered breathing * is a nightshift worker * uses sleep medication

Keywords: school-age child
type 1 diabetes and obstructive sleep apnea

Conditions: Sleep Apnea, Obstructive; Type 1 Diabetes (T1D)

Summary: the purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with type 1 diabetes.

obstructive sleep apnea (osa) is a common sleep disorder characterized by recurrent collapse of upper airway during sleep, resulting in intermittent hypoxia, sleep fragmentation by transient arousals, and poor sleep quality. continuous positive airway pressure (cpap), applied at night, is considered the treatment of choice for persons who are diagnosed with osa. current evidence suggests that osa is highly prevalent in adults with t1d and particularly those with moderate-to-severe osa have poorer glycemic control. our overall goal is to investigate the role osa in glycemic dysregulation in adults with t1d.

Eligibility criteria:
inclusion criteria: * age: 18 to 50 years old * type 1 diabetes (duration 3-20 years) on insulin pump therapy and using a cgm device with an gmi (glucose management indicator) between 5.5 and 8.5% with hemoglobin in the normal range at screening * moderate to severe osa by home sleep apnea test exclusion criteria: * regular and adherent cpap use per clinical guidelines * requiring oxygen or advanced positive airway pressure modalities during sleep * having a 'fall-asleep' or 'near miss' accident in the past 6-months * shift work * severe hypoglycemia (≥1 episode in the past 3 months or diagnosis of hypoglycemic unawareness) * ≥1 trip to emergency room for poor glucose management in the past 6 months * proliferative retinopathy * fasting triglycerides \>400mg/dl, * liver transaminases \>2 times upper limit of normal, * renal transplantation or serum creatinine \>1.5 mg/dl * anemia (hemoglobin \<13.0g/dl in men or \<11.6g/dl in women) * acute coronary syndrome or stroke past 6 months * severe hypertension (blood pressure\>180/105 mmhg) * any other significant health condition: unstable angina, heart failure requiring hospitalization in the past 6 months, significant heart block or arrhythmias, nyha class\>2, pulmonary disease with dependence on oxygen or daily use of bronchodilators, active or chronic infection, thyroid disease and other endocrine disorders (e.g. cushing syndrome, acromegaly) * recent major surgery * major psychiatric disorder * subjects will also be excluded if taking medications that can confound metabolic assessments including systemic glucocorticoids, antipsychotics, thiazide diuretics, beta-blockers, daily use of aminophylline or theophylline, or use of any immunosuppressant. * currently pregnant or trying to get pregnant or nursing * smoking, alcohol or illegal drug abuse
neuromuscular blocking agents utilized during perioperative hypersensitivity evaluation

Conditions: Allergy

Summary: the researchers are trying to develop an allergy skin test to help predict allergic responses to medications commonly given to patients during surgery.

this study will be a prospective study to accurately determine the negative predictive value of skin testing with nmbas. it is hypothesized that the concentrations that should be used for nmbas are actually much lower than previously recommended and that the higher incidence of identifiable nmba induced allergic reactions during anesthesia in the past may be due to irritation of the skin rather than a true allergic reaction (false positives).

Eligibility criteria:
inclusion criteria: * all adults \> or = to 18 y/o undergoing surgery exclusion criteria: * minors under the age of 18 y/o, adults unable to consent, or those adults with previous allergic reaction history during previous surgeries.
relationship of endoplasmic reticulum stress and adenoid diseases

Conditions: Adenoiditis Acute Infective

Summary: adenoid tissue is a significant organ for the performing of immune systems in children. the endoplasmic reticulum (er), is an organelle needed for the care of a stable function of cells. the purpose of the study was to explore the correlation among er stress and adenoid tissue disorders and to explain the structure of diseases related to the immune system.


Eligibility criteria:
inclusion criteria: - patients with the clinical diagnosis of chronic adenoiditis and adenoid hypertrophy. exclusion criteria: * systemic diseases * other otolaryngological

Keywords: adenoidectomy ; endoplasmic reticulum
the effect of web-based education in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Educational Problems

Summary: this research was designed as a randomized controlled study to develop a web-based training program and evaluate the program's impact on diabetes management. this research was carried out on 89 patients diagnosed with type 2 diabetes in the department of endocrinology and metabolic diseases of akdeniz university. the preparation of the web page and its content has benefited from the latest literature, national and international websites, and expert opinions. individuals in the survey scope have been stratified random method with as intervention group (n=44) and control group (n=45). individuals who were taken in the initiative group were informed by web page, sms, e-mail prepared for a period of three months. personal information forms metabolic control variable form, diabetes self-care activities questionnaire, self-efficacy scale for type 2 diabetic individuals, diabetes-specific quality of life scale and web site analysis and measurement inventory were used as the data tools. the informed consent was obtained from the patients and all data were collected by author during face-to-face interviews.


Eligibility criteria:
inclusion criteria: * between the ages of 18-65 * diagnosed with type 2 diabetes at least six months ago * not have communication disabilities * used insulin * phone and internet connection exclusion criteria: * have a physical, cognitive or mental disability to answer questions

Keywords: nursing type 2 diabetes web based education program self efficacy quality of life
dose-escalation study of combination bms-936558 (mdx-1106) and ipilimumab in subjects with unresectable stage iii or stage iv malignant melanoma

Conditions: Malignant Melanoma

Summary: the purpose of this study is to determine the safety and tolerability of treatment with bms-936558 (mdx-1106) in combination with ipilimumab (bms-734016) when given at the same time or as a sequenced regimen in subjects with unresectable stage iii or stage iv malignant melanoma (mel)


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * histologic diagnosis of malignant melanoma (mel) * measurable unresectable stage iii or iv mel * ecog performance status score of 0 or 1 * life expectancy ≥4 months * for those enrolled in amendment 5 and later, tumor tissue (archival or recent acquisition) must be available * for cohorts 1-5, subjects may have been treated with up to 3 prior systemic standard treatments for metastatic melanoma not including any post-incisional adjuvant therapy. subjects may be treatment naïve. all metastatic melanoma regardless of primary site of disease will be allowed * for cohorts 6-7, subjects may have been treated with up to 3 prior systemic standard treatments for metastatic melanoma; this does not include any post-incisional adjuvant therapy. specifically, subjects must have received ≥3 doses of ipilimumab therapy and the last dose having been administered within 4-12 weeks of initiation of study treatment exclusion criteria: * history of severe hypersensitivity reactions to other mabs * prior malignancy active within the previous 2 years except for localized cancers that are considered to have been cured and in the opinion of the investigator present a low risk for recurrence * active autoimmune disease or a history of known or suspected autoimmune disease * history of recently active diverticulitis or symptomatic peptic ulcer disease and history of adrenal insufficiency * regular narcotic analgesia * active, untreated central nervous system metastasis * for subjects enrolled in cohorts 1-5, prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137 or anti-ctla-4 antibody * for subjects enrolled in cohorts 6-7, prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, or anti-cd137 antibodies * any non-oncology vaccine therapy used for prevention of infectious disease * concomitant therapy with any other anti-cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other investigational drugs * positive tests for human immunodeficiency virus (hiv), acquired immunodeficiency syndrome (aids), hepatitis b, hepatitis c * subjects weighing ≥125 kg are excluded from cohort 5 * subjects in cohorts 6 and 7 must have received ipilimumab monotherapy immediately prior to study entry, but must not have received that ipilimumab as part of a clinical trial * subjects with ocular melanoma are excluded from cohort 8
level of dna-fragmentation before and after antioxidant-based therapies in male infertility

Conditions: Infertility, Male

Summary: the investigators will investigate the effect of antioxidants and lifestyle factors on the level of oxidative stress. as oxidative stress cannot be directly measured, it will be approximated by the dna fragmentation index (dfi) which reflects the level of dna damage in sperm caused by oxidative stress.

this is a one-site prospective exploratory study at the university clinic for gynaecological endocrinology and reproductive medicine in bern. on total 78 men with male infertility will be recruited. the primary objective of the study is to assess the effectiveness of 3 months of antioxidant-based therapy on changing patients' dfi level. the objective of the study is to assess the effect of 3 months of antioxidant-based therapy on the level of dfi. we are primarily interested in testing whether the treatment effectiveness (i.e. the change in dfi level) depends on the initial level (i.e. before treatment) and treatment adherence. the data will be collected by the physicians and added to the redcap study registry. access to the total data set is only permitted for the principal investigator.

Eligibility criteria:
inclusion criteria: * willing to participate * written consent * men with infertility problems who want to start an infertility treatment with their partner exclusion criteria: * no measurement of dna fragmentation possible * intake of prescribed medications * exposure to toxins * chronic diseases

Keywords: antioxidant dna-fragmentation oxidation-reduction potential lifestyle
a trial investigating the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals versus insulin detemir once or twice daily plus meal time insulin aspart in children and adolescents with type 1 diabetes mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in asia, europe and north and south america. the aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in children and adolescents with type 1 diabetes mellitus.


Eligibility criteria:
inclusion criteria: - informed consent obtained before any trial related activities. trial related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - subjects diagnosed with type 1 diabetes mellitus - hba1c below or equal to 11.0% exclusion criteria: - known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by the investigator - more than 1 episode of diabetic ketoacidosis requiring hospitalisation within the last 3 months prior to visit 1 (screening) - any chronic disorder or significant concomitant disease, which in the investigator's opinion might jeopardise the subject's safety or compliance with the protocol
china resolute integrity 34/38 mm study

Conditions: Ischemic Heart Disease; Stenotic Coronary Lesion; Cardiovascular Diseases; Arteriosclerosis; Coronary Artery Disease

Summary: to evaluate the clinical safety and efficacy in chinese subjects, eligible for percutaneous transluminal coronary angioplasty (ptca) in lesions amenable to treatment with a 34/38 mm medtronic resolute integrity™ zotarolimus-eluting coronary stent system.


Eligibility criteria:
key inclusion criteria: * the subject is an acceptable candidate for treatment with a drug-eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, the instructions for use of the resolute integrity 34/38 mm stent * the subject can have either a single lesion, or two lesions located in separate target vessels treated during the index procedure. each lesion length needs to be ≤35mm with at least one lesion length \>27mm and≤ 35mm and amenable for treatment with a resolute integrity 34/38 mm stent key exclusion criteria: * stemi within 24 hours * left main disease * bifurcation disease

Keywords: long lesion in-stent late lumen loss (lll) major adverse cardiac events (mace) myocardial infarction (mi) target vessel revascularization (tvr) target lesion revascularization (tlr) target vessel failure (tvf) target lesion failure (tlf) stent thrombosis (st)
a study to evaluate efficacy and safety of hs-10374 for moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: this study has been designed to explore the clinical efficacy and safety of hs-10374 in the treatment of moderate to severe plaque psoriasis. additionally, this study is to find the optimal dosing for the future clinical development of hs-10374.

this is a 12-week, multi-center, randomized, double blind, placebo-controlled, phase 2 study. the study duration includes a 4-week screening period, a 12-week treatment period, and a 4-week follow-up period. all eligible subjects will be randomly assigned to 1 of 3 treatment arms (hs-10374 dose 1, hs-10374 dose 2, and placebo) in an equal ratio.

Eligibility criteria:
inclusion criteria: 1. male or female subjects between the ages of 18-70 years 2. diagnosis of plaque psoriasis for at least 6 months 3. eligible for phototherapy or systemic therapy 4. plaque covering ≥ 10% of bsa 5. pasi ≥ 12, spga ≥3 exclusion criteria: 1. diagnosis of non-plaque psoriasis or drug-induced psoriasis 2. recent history of infection, history or risk of serious infection 3. any major illness or evidence of unstable condition of major organ systems including psychiatric disease 4. any condition possibly affecting the pk process of the study drug 5. evidence of other skin conditions that would interfere with the evaluation of psoriasis 6. history of hypersensitivity to the ingredients of study drugs, history of anaphylaxis 7. history of lack of response to any therapeutic agent targeted to il-12, il-17 or il-23 at approved doses after at least 3 months of therapy 8. have received the prohibited treatment during the protocol required washout period 9. any significant laboratory or procedure abnormalities that might place the subject at unacceptable risk during this study period
hkt-500-us12 in adult patients with oa knee pain

Conditions: Osteoarthritis, Knee

Summary: the objective of this study is to characterize the analgesic properties of single dose study of hkt-500 in subjects with pain caused by mild to moderate oa of the knee

a randomized, multicenter, double-blind, single dose study of the analgesic properties of hkt-500 and placebo in subjects with pain caused by mild to moderate osteoarthritis of the knee

Eligibility criteria:
inclusion criteria: * male or female 45 years of age or older * with osteoarthritis of the knee exclusion criteria: * subject is a woman of childbearing potential * who has a positive urine pregnancy test, * is lactating, or who is not surgically sterile

Keywords: osteoarthritis,knee,ketoprofen,pain,patch,analgesic
the role of genetic factors in the development of atopic dermatitis in the kazakh population

Conditions: Atopic Dermatitis

Summary: this is a gwas study that aims to identify possible candidate genes associate to atopic dermatitisby exploring single nucleotide polymorphism (snp) in a group of atopic dermatitis, in the kazakh population. the investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find snp significantly associate with atopic dermatitis

a genome-wide association study (gwas) is an approach used in genetics research to associate specific genetic variations with particular diseases. the method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Eligibility criteria:
inclusion criteria: * persons with various forms of a confirmed diagnosis of atopic dermatitis; * the age of the patients is from 18 to 45+ years; * persons of kazakh nationality, whose paternal and maternal grandparents are kazakhs. * persons who are able and willing to provide written informed consent; * persons capable and willing to comply with the research protocol; exclusion criteria: * persons under the age of 18; * patients with severe concomitant systemic diseases, including cardiovascular, respiratory, hepatic and renal failure * patients with severe infectious processes (sepsis, abscess, hepatitis b and c, hiv) * persons with mental illness. * persons taking corticosteroid drugs, immunosuppressants within the last month; * persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; * pregnant or lactating women; * tuberculosis of any localization in the active phase and in history; * severe and decompensated diseases of the liver and kidneys, cardiovascular system; * severe and decompensated course of endocrine diseases; * autoimmune diseases; * systemic diseases; * oncological diseases;

Keywords: gwas
development of an optimal algorithm for the management of patients with retinal pigment epithelium detachment in neovascular age-related macular degeneration using artificial intelligence

Conditions: Neovascular Age-related Macular Degeneration

Summary: the study involves the development of an algorithm for predicting anatomical and functional results of therapy with angiogenesis inhibitors in patients with retinal pigment epithelium detachments in neovascular age-related macular degeneration, based on primary optical coherence tomography of the macular zone and clinical data.

patients were divided into 3 groups according to the results of therapy: adhesion of detachment, lack of adherence to detachment, rupture of detachment. for these groups, oct images of the macular zone with maximum detachment before therapy are selected. these images, along with other clinical parameters, are input to the algorithm. the result is one of the 3 treatment outcomes listed above. the methods that will be used to develop the algorithm include methods for processing and transforming data, deep machine learning, metrics for calculating the accuracy of algorithms.

Eligibility criteria:
inclusion criteria: * linear b - scan through the macular area with the longest detachment * other pathologies exclusion criteria: * images without detachment * images on which it is possible to diagnose the need for therapy only in the presence of additional factors not considered in the study.

Keywords: machine learning artificial intelligence anti-vegf therapy amd